Atea Pharmaceuticals

IPO

Committed to the discovery, development and commercialization of oral direct-acting antiviral therapies.

Public · Boston, United States · Founded 2014 · $215.0M raised

Employees
51–200
Founded
2014
Business Model
B2B
Total Funding
$215.0M
Last Round
$215.0M Series DMay 2020
Rounds
1
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral direct-acting antiviral therapies for serious viral diseases with unmet medical needs. Its lead program is a fixed-dose combination of bemnifosbuvir and ruzasvir in Phase 3 development for hepatitis C virus, with topline data from the C-BEYOND trial expected mid-2026. Atea also has early-stage programs targeting dengue and RSV.

Summary

Atea Pharmaceuticals is a Biotech company based in Boston, United States, founded in 2014. It has raised $215.0M in total across 1 round, most recently a $215.0M Series D round in May 2020. Investors include Bain Capital Life Sciences, RA Capital Management and Perceptive Advisors.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOOct 2020
$300.0M

Sign up to see all 2 events

Funding: Series D. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Atea Pharmaceuticals on Indexed.vc
<a href="https://indexed.vc/companies/atea-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/atea-pharmaceuticals" alt="Atea Pharmaceuticals on Indexed.vc" width="260" height="76" /></a>